Description |
Carnosol is a potent Ribosomal S6 Kinase (RSK2) inhibitor that could be useful for treating gastric cancer, with an IC50 of ~5.5 μM.
|
Target |
IC50: 5.5 μM (RSK2)[1].
|
In Vitro |
It is showed that carnosol has no cytotoxic effects on GES1 cells and 10 μM carnosol strongly suppresses RSK2 activity, but has little effect on any other kinase. Carnosol exerts strong dose-dependent inhibitory effects against RSK2 autophosphorylation and phosphorylation of its substrate ATF1[1].
|
In Vivo |
Results indicate that Carnosol significantly decreaseS the volume and weight of gastric tumors relative to the vehicle-treated group. Additionally, mice tolerate treatment with carnosol without significant loss of body weight similar to the vehicle-treated group. The phosphorylation of CREB, a direct downstream protein of RSK2, Is strongly inhibited in the carnosol-treated group but the expression of total CREB is relatively unchanged[1].
|
Animal Admin |
Mice[1] Mice are orally administrated Carnosol at 100 mg/kg or vehicle 5 times a week over a period of 31 days[1].
|
Density | 1.3±0.1 g/cm3 |
Boiling Point | 524.8±50.0 °C at 760 mmHg |
Flash Point | 187.0±23.6 °C |
Exact Mass | 330.183105 |
PSA | 66.76000 |
LogP | 3.71 |
Vapour Pressure | 0.0±1.4 mmHg at 25°C |
Storage condition | −20°C |